Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
This study is currently recruiting participants.
Verified April 2013 by National Cancer Institute (NCI)
Study NCT01567709
Information provided by National Cancer Institute (NCI)
First Received on March 29, 2012.
Last Updated on April 9, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
